Encouraging results reported from trial of Merck AIDS vaccine

Results from clinical tests of a Merck AIDS vaccine have been better than expected, prompting the researchers to double enrollment in the trial to 3,000 participants. The study is examining healthy volunteers to determine their immune response to the vaccine, and the trial later may indicate whether the immune reactions can prevent or control AIDS.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX